Teleflex Incorporated Showcases New Clinical Data Presented At the 2025 American Urological Association Annual Meeting

Published: 2025-05-15 06:30:00 ET TFX

Published on 05/15/2025 at 06:30, updated on 05/15/2025 at 07:51

Teleflex Incorporated announced the presentation of compelling new clinical data at the 2025 American Urological Association (AUA) Annual Meeting in Las Vegas, held April 26-29. Data from two randomized controlled trials (RCTs) reinforce the UroLift?? System's advantages compared with Rezum and tamsulosin, particularly in terms of early patient satisfaction, rapid symptom relief, and sexual function outcomes.

The following research presentations outlined the key findings from the studies: Results from the CLEAR RCT Suggest Factors Corresponding to Early Patient Satisfaction Are Better Following UroLift PUL vs. Rezum WVTT1+ Men treated with the UroLift System were significantly more satisfied with their results at two weeks and at one month after treatment. Those who received the UroLift System procedure also had shorter catheterization times, better symptom relief, and better sexual function outcomes during the early recovery period compared to Rezum patients.

UroLift PUL Demonstrates Significantly Better Efficacy and Patient Experience Outcomes vs. Tamsulosin: Results from the IMPACT RCT2?. At three months, men who were treated with the UroLift?

System showed significantly better symptom improvement compared to those who took medication. UroLift? System patients reported better sexual function outcomes and overall experience.?

In fact, 70% of men randomized to the medication treatment arm eventually chose to crossover to the UroLift? System.